R-Pharm Pharmaceutical Company

R-Pharm JSC is a Russian pharmaceutical company engaged in the development, research, production, and launch of a wide range of drugs intended mainly for inpatient and specialized medical care.

Aktivs

The holding structure includes pharmaceutical complexes located in Yaroslavl, Kostroma region, Novosibirsk, Germany, a modern scientific and production complex for the synthesis of active pharmaceutical substances in Rostov is being built.

As of July 2016, the company has more than 3,500 specialists. R-Pharm operates throughout the Russian Federation, in the CIS, USA, Germany, Japan, Turkey and India. There are more than 60 branches and representative offices.

Areas of activity

The main areas of activity are:

• production of finished dosage forms,
• active pharmaceutical ingredients of chemical nature and biotechnological substances,
• research and development of innovative drugs and technologies,
• bringing modern medicines to market, and
• training and training of specialists for the pharmaceutical industry and health care.

Performance indicators

2020: Revenue - 120.5 billion rubles. (+ 46%), profit - 17.9 billion rubles. (49%)

On August 13, 2021, information appeared that the profit of R-Pharm for the year increased by 49% - from 12 billion in 2019 to 17.9 billion rubles in 2020. The company's revenue grew by 46% - to 120.5 billion rubles.^[1]

History

2024: Purchase of Baltpharma

On July 31, 2024, it became known that R-Pharm acquired a resident of the Baltpharm St. Petersburg special economic zone to fulfill the terms of the first offset contract. Vice-Governor of St. Petersburg Oleg Ergashev noted that this deal will allow R-Pharm to build a pharmaceutical plant on time at the Novoorlovskaya site. Read more here

2023

Opening of the Center for Clinical Research of Medicinal Products in Oncology together with Sechenov University

The Center for Clinical Research of Drugs in Oncology, organized jointly with the R-Pharm group of companies, will open at Sechenov University. An agreement on this was signed on November 8. The Center will be headed by Marina Sekacheva, Director of the Institute of Personalized Oncology, Sechenov University, Professor, Doctor of Medical Sciences. Read more here.

Bringing KOEK Microfluidic Chips to Market for Sperm Sorting

The R-Pharm Group of Companies received a marketing authorization (RZN 2023/21148 from 22.09.2023) for FERTILE, FERTILE PLUS and FERTILE ULTIMATE microfluidic chips. These are sterile products for single use, the principle of which is to separate sperm by their motility in the microenvironment. The project is being implemented under an agreement with the Turkish biotechnology company Koek Biotechnology. R-Pharm announced this on October 30, 2023. Read more here.

Production of medicines on the territory of the SEZ "Technopolice Moscow" at the sites in Pechatniki and Alabushevo

The R-Pharm group of companies localizes the production of pharmaceutical drugs in the territory of the special economic zone (SEZ) "Technopolice Moscow" at the sites in Pechatniki and Alabushevo. Oncohematological and oncological drugs, medicines for the treatment of diabetes mellitus and others will be produced here. This was announced on June 28, 2023 by the Deputy Mayor of Moscow for Economic Policy and Property and Land Relations Vladimir Efimov.

In 2023, the Moscow government signed two offset contracts with the company for the supply of medicines. During the entire period of their validity, the city will buy products worth almost six billion rubles from the enterprise. Production will be established at two sites of the Technopolice Moscow special economic zone, where drugs under 14 international non-proprietary names will be produced in aggregate, told Vladimir Efimov.

As part of one of the contracts at the sites of the capital's SEZ in Pechatniki and Alabushevo, the company localizes the production of drugs under 10 international non-proprietary names, among them: oncohematological and oncological drugs, drugs for the treatment of diabetes mellitus, cardiovascular, rheumatological, neurological diseases and nonspecific ulcerative colitis. The volume of investments will be at least three billion rubles. In return, the city will purchase almost 150 million tablets and capsules worth almost 4.8 billion rubles within five years.

Under the second contract concluded with R-Pharm, immunosuppressive drugs and anticancer drugs under four international non-proprietary names will be produced at the sites. The company will invest at least 800 million rubles in the implementation of this contract, in return the city will provide it with the purchase of over 357 thousand units of products worth more than a billion rubles. The first deliveries of drugs to the capital's medical institutions under both contracts will begin in 2025-2026, told the head of investment the Department industrial politicians and Moscow Vladislav Ovchinsky.

The city has signed 12 offset contracts for medicines, medical devices and food for dairy kitchens. The total investment will amount to more than 19 billion rubles.

In 2022, amendments to the law on the contract system came into force, lowering the minimum threshold for investments in the creation or modernization of production within the offset from a billion to 100 million rubles. This allows many more manufacturers to be involved in the conclusion of agreements. It also became possible to sign offset tests together with two or more regions of Russia. The minimum investment under such an inter-subject contract will amount to 400 million rubles, and in the case of purchases carried out in 2022-2023 - 100 million rubles. So, in April 2023, Moscow Mayor Sergei Sobyanin approved a competition for the conclusion of an interregional offset contract. It is aimed at purchasing medical devices in two regions - Moscow and the Samara region. The investor undertakes to invest at least 100 million rubles in the production of nitrile gloves and localize it in the Samara region in 2024.

Withdrawal from Albiogen's capital

At the end of June 2023, it became known that the manufacturer of drugs "R-Farm," founded by businessman Alexei Repik, left the capital of the distributor of foreign equipment for genetic research "Albiogen." Read more here.

Agreement in order to create the production of medicines in the territory of St. Petersburg

On June 15, 2023, the General Director of R-Pharm JSC Vasily Ignatiev and the Vice-Governor of St. Petersburg Alexei Korabelnikov signed an agreement on cooperation in the implementation of an investment project to create, modernize, master the production of medicines in St. Petersburg.

The signed agreement assumes that R-Pharm, which is planned to be launched under an offset contract concluded in 2023, will launch the production of active pharmaceutical substances and at least 40 INN of finished drugs, as well as create 300 additional jobs.

The offset contract between R-Pharm and the Government of St. Petersburg, which became the first in the history of the city, was concluded in January 2023. In accordance with the offset, by 2026, the R-Pharm group of companies will create a high-tech full-cycle pharmaceutical production in St. Petersburg and will launch the production of drugs for the treatment of cancer, cardiovascular diseases and diabetes mellitus.

Шаблон:Quote 'author=said R-Pharm CEO Vasily Ignatiev.

Plan for the launch of two research centers based on the Sputnik Technopolice plant

By the end of 2023, R-Pharm will launch two research centers (- R&D centres) for the development of biological chemical medical and drugs. Objects with a total area of ​ ​ more than five thousand square meters will be opened on the basis of the plant "." Sputnik Technopolice More. here

Investing 4 billion rubles in a plant in St. Petersburg

R-Pharm invests more than 4 billion rubles in the construction of the production of medicines in St. Petersburg. This was announced at the end of February 2023 by the press service of the city governor's administration.

In particular, 2.9 billion rubles will be allocated for the construction of the plant and equipping it with equipment, 1.2 billion rubles for research and design work and technology development. During the implementation of the project, about 300 jobs will be created.

Earlier it was reported that R-Pharm plans to build the production of drugs in St. Petersburg by 2026 as part of the first offset contract. In January 2023, the government of St. Petersburg and R-Pharm signed a contract for a period of 10 years. Under the terms of the contract, the city authorities for 7 years after the completion of the construction of the enterprise will purchase drugs from the company totaling 8.7 billion rubles.

According to the project, the company is supposed to produce 31 pharmaceuticals, including analogues of drugs for the treatment of cancer, cardiovascular, neurological diseases, as well as diabetes mellitus.

The result of the competition, of course, is unexpected. I was more inclined to believe that the St. Petersburg company would still receive an offset contract, "says Nikolai Bespalov, Development Director of RNC Pharma.

According to the expert, it must be recognized that the winner of the auction has great competencies in the production sector and issues of international cooperation, has vast experience in working with a state contract.

R-Pharma does not have production sites in St. Petersburg. When asked if the place where the new plant will be located is already known, the press service of Kommersant replied that they are not yet ready to comment on the details of the project.^[2]

2022

The beginning of the development of antitumor drugs together with the Pushchinsky Scientific Center

On December 5, 2022, the R-Pharm Group and the Pushchinsky Research Center for Biological Research of the Russian Academy of Sciences announced the start of joint work on the development of the latest generation of anticancer drugs. Scientific research will be carried out on the basis of a laboratory created with the financial and organizational support of R-Pharm within the framework of the New Medicine technological platform of the Ministry of Education and Science of Russia.

Scientists of the Pushchinsky Scientific Center will develop bispecific drug candidates for the therapy of cancer based on small polypeptides conjugated with chemical toxins. Molecular tests will be carried out with the direct participation of the R-Pharm group of companies. R-Pharm's investment in the project will amount to 5 million rubles at the initial stage and, if necessary, can be increased.

The profile of the laboratory created with the participation of the R-Pharm group of companies has scientific novelty not only for the Pushchinsky Center. There are so far few such topics in our country, in principle, who have dealt with. But we expect that the industrial experience of R-Pharm, multiplied by the research experience of the center's employees, will expand therapeutic opportunities in the fight against cancer, says Andrey Yakovenko, director of biotechnology projects at R-Pharm.

We are grateful to the R-Pharm Group for the organizational and financial support of our project. The study of the capabilities of bispecific drug candidates created on the basis of small peptides, as well as the development of such products, is quite justifiably considered a promising approach in finding effective methods of anti-tumor therapy, "said Sergey Permyakov, director of the Institute of Biological Instrumentation of the Russian Academy of Sciences.

Within the framework of the large technological platform "New Medicine," Ministry of Education and Science Russia another joint project "R-Pharm" and the Russian Academy of Sciences is being implemented - a Institute of Organic Chemistry named after N.D. Zelinsky RAS laboratory has been created that will focus on the development of conjugated carbohydrate vaccines (the so-called "glycovaccin") against antibiotic-resistant pathogens of hospital infections.

Opening a laboratory for the development of glycovaccine at the Institute of Organic Chemistry named after N.D. Zelinsky RAS

At the Institute of Organic Chemistry named after N.D. Zelinsky RAS (IOH RAS), with the financial and organizational support of the R-Pharm group of companies, a specialized laboratory has been created that will focus on the development of conjugated carbohydrate vaccines (the so-called "glycovaccin") against antibiotic-resistant pathogens of hospital infections. The R-Pharm company announced this on November 28, 2022.

Among other things, R-Pharm will take part in biological tests of developed high-tech products.

The relevance of glycovaccine development is dictated by the increasing resistance of pathogens, primarily bacteria, fungi and yeast. To expand research activities in this direction, on the basis of a group of candidate of chemical sciences Vadim Krylov in the laboratory of glycoconjugate chemistry of the IOH RAS, headed by corresponding member of the RAS Nikolai Nifantiev, a laboratory of synthetic glycovaccin was created. The application for the creation of the laboratory was the winners of the grant competition for youth laboratories, recently held by the Ministry of Education and Science of Russia. The R-Pharm group of companies, which has been actively cooperating with the IOH RAS in this area for more than 5 years, has been an industrial partner in this project.

The development of glycovaccine remains one of the most promising directions in the search for effective ways to counter resistant pathogens. We have been interacting with the Institute's team for several years, we know the capabilities of the project team well and we hope that by joint efforts we will achieve the necessary results, "said Vasily Ignatiev, General Director of R-Pharm.

Glycovaccins are able to fight many dangerous pathogens, including pneumococcus, aspergillosis, pseudomonas bacillus. Our institute has already advanced far in the development of conjugated vaccines and the development of technologies for the production of carrier proteins, however, financial and organizational support for such an industrial partner as R-Pharm will bring this work to a different level, "said Nikolai Nifantyev, Corresponding Member of the Russian Academy of Sciences.

Opening of a representative office in Hanoi

On November 2, 2022, the R-Farm Group of Companies announced the opening of its representative office in the capital of the Socialist Republic of Vietnam - the city of Hanoi. The representative office will focus on the tasks of registering and promoting the portfolio of its own medicines of the group of companies - both in the territory of the Socialist Republic of Vietnam itself and in other neighboring states of Southeast Asia.

As of November 2022, Vietnam is one of the leaders in the Asia-Pacific region in the field of organizing and conducting preclinical research, more than thirty pharmaceutical companies operate in the country, including leading international corporations. The most important aspect of the activities of the R-Pharm representative office will be cooperation with major scientific institutes and research centers.

At the first stage, the group's priority tasks will be the selection of laboratories for preclinical research, which are necessary to work on its own portfolio of biosimilars, as well as the registration of R-Pharm flagship drugs.

R-Pharm continues to implement a long-term strategy to expand international cooperation in the field of biopharma. The opening of a representative office in Hanoi gives the "green light" for R-Pharm to enter other countries of the region, and also strengthens the company's position in terms of developing its own original drugs for the Russian and global markets, - said the commercial director of R-Pharm Andrei Burkhanov.

Attracting 800 million investments

In July 2022, the expert council of the Industrial Development Fund (FRP) approved 12 loans for the implementation of projects in various regions of the country in the amount of more than 5.33 billion rubles. Among them is the project of the R-Pharm group. Read more here.

2021

R-Pharm is the sole owner of R2med

At the end of November 2021, it became known about the withdrawal of Rusatom Healthcare (a subsidiary of Rosatom) from a joint venture with R-Pharm - LLC |R2med. This company produces radiopharmaceuticals used to treat severe diseases. Read more here.

The AstraZeneca vaccine produced in Russia was called "R-Covi"

On March 12, 2021, the name became known, coronavirus vaccines COVID-19 which, under the license of the British pharmaceutical company AstraZeneca Oxford University , will be produced by the Russian company R-Pharm. More. here

Completion of the transaction for the purchase of the Teva pharmaceutical plant in the Novosyolki technopark

On February 19, 2021, the R-Pharm group of companies and Teva announced the successful completion of the transaction for the acquisition of R-Pharm of the Teva pharmaceutical plant located in the Yaroslavl Industrial Park (Novosyolki). The purchase of a complex certified according to the GMP standard and producing drugs for the treatment of socially significant diseases will allow R-Pharm to adapt production facilities to the needs of the healthcare system. Read more here.

Completion of an investment transaction in Sber Eapteka

On February 10, 2021, Sber Eapteka informed Zdrav.Expert about the completion of the transaction for joint investment in it by Sberbank and the R-Pharm Group of Companies. Read more here.

2020

Acquisition of Teva Pharmaceutical Plant in Novosyolki Technopark

On December 2, 2020, it became known that Teva was selling a pharmaceutical enterprise located on the territory of the Yaroslavl Industrial Park (Novosyolki) to the R-Pharm group of companies. The amount of the transaction was not disclosed. Read more here.

Acquisition of a stake in Eaptek

On October 22, 2020, Eapteka told TAdviser that as part of the transaction, Sberbank and the R-Pharm Group of Companies, after receiving the necessary antimonopoly approvals, will acquire 45% of the company's shares, while the founder and CEO of Eapteka Anton Buzdalin will retain 10%. Read more here.

Cooperation with AstraZeneca in the production and export supply of vaccine against COVID-19

On July 17, 2020, AstraZeneca and R-Pharm announced cooperation in the production of a recombinant adenovirus vaccine to prevent COVID-19 infection caused by the SARS-CoV-2 virus in Russia. Read more here.

Creating a joint company with Canon Medical

On June 22, 2020, it became known about the creation of a joint venture between R-Pharm and Canon Medical Systems. It will supply and service Canon diagnostic medical equipment in Azerbaijan, Armenia, Belarus, Kazakhstan, Kyrgyzstan, the Russian Federation, Tajikistan, Turkmenistan and Uzbekistan. Read more here.

Plans to create a joint venture together with RDIF in the fight against COVID-19

On June 10, 2020, the Russian Direct Investment Fund (RDIF), the Sovereign Wealth Fund of the Russian Federation and the R-Pharm group of companies announced a partnership as part of efforts to combat coronavirus infection and produce a Russian vaccine with high export potential.

To implement a comprehensive partnership, RDIF and R-Pharm agreed to create a joint venture (JV) with an investment volume of more than 4 billion rubles. The JV will carry out work in a number of areas, including:

• Scaling the production of Artlegia (olokizumab), used in the treatment of cytokine storm (excessive immune system response) in patients with moderate coronavirus infection. On May 21, 2020, R-Pharm Group of Companies completed the registration of Artlegia for rheumatoid arthritis, and on June 3 it was included in the guidelines Ministry of Health Russia for the prevention, diagnosis and treatment of a new coronavirus infection;
• Production of Russian vaccines against coronavirus infection, the development of which is carried out by the "" National Research Center for Epidemiology and Microbiology named after Honorary Academician N.F. Gamalei Ministry; health care RUSSIAN FEDERATION
• Development and production of other promising biotechnological medicines and vaccines for the fight against coronavirus.

Within the framework of the joint venture in Yaroslavl, a modern biotechnological production of active pharmaceutical substances and finished dosage forms will be built with the possibility of exporting products to the market of the Middle East and other countries.

As of June 2020, the drug is produced and labeled at the production complex of the R-Pharm group of companies in Yaroslavl. As of June 10, 2020, more than 12 thousand packages with the digital code Data Matrix were released into civil circulation.

Kirill Dmitriyev, CEO of the Russian Direct Investment Fund (RDIF), said: {{quote 'RDIF is focused on a comprehensive search for effective means against coronavirus. Earlier, together with the KhimRar Group of Companies, the production of Avifavir, one of two drugs in the world registered against coronavirus and a drug based on Favipiravir, approved for the treatment of coronavirus, was launched. Within the framework of the joint venture with R-Pharm Group of Companies, we intend to focus efforts on another area of ​ ​ therapy for coronavirus infection and support the creation of a domestic vaccine, as well as expand the production of Artlegia. We consider it important to maximize the toolkit of doctors in the therapy of patients with coronavirus infection and limit its negative consequences for the body. }}

Alexey Repik, Chairman of the Board of Directors of the R-Pharm Group of Companies, noted: {{quote 'Partnership with RDIF is an important part of R-Farm's comprehensive strategy to combat COVID-19. The medicine we have developed has already been included in the recommendations of the Russian Ministry of Health and has become one of the key tools for the therapy of complications from coronavirus infection. We are talking about an original Russian biotechnological drug to prevent a cytokine storm - olokizumab. Together with RDIF, we intend to scale its production and provide patients with the drug not only in Russia, but also abroad. Our program also includes clinical studies of the original RPH-104 molecule, a IL-1 blocker, these are joint trials with olokizumab. Another biotechnological RPH-137 molecule, the so-called "trap" for the virus, should make a significant contribution to getting rid of the burden of the virus. Another vector is the work on the vaccine. The project is very ambitious. The vaccine being developed at the N.F. Gamaleya Research Institute of Epidemiology and Microbiology seems to be the most promising of the Russian ones in many respects. We expect that after the completion of development it will be produced at the R-Pharm plant in Yaroslavl, which we will open together with RDIF "}}

2019: Crowding out foreign drugs with their own generics

In 2019, the domestic company R-Farm Alexei Repik is ousting foreigners from the Russian drug market. The company does not hesitate to register analogues of drugs, at the same time releasing originals at its own facilities. In the case of the antiretroviral drug with INN Atazanavir-TL, this led to the fact that the owner of the original drug Reataz, the American Bristol-Myers Squibb, stopped selling in Russia. The manufacturer explained its decision by the loss of government orders for the supply of Reataz in connection with the emergence of analogues.

It is worth recalling that R-Pharm is one of the largest operators of state orders. According to SPARK-Interfax, in 2018, R-Pharm JSC received 57.7 billion rubles. revenue and 5.2 billion rubles. net profit.

To expand its potential in the public procurement market, the pharmaceutical company is actively expanding the line of analogues of foreign drugs. And now she has developed her own version of the expensive anesthetic Sevoran, produced by the American AbbVie at the R-Farm plant in Yaroslavl. It is worth noting that sales of Sevoran go on gigantic volumes in 2018 sold 193.9 thousand packages worth 1.8 billion rubles.

In the future, the Russian generic of identical quality will completely replace the American medicine on the Russian market. Logically, the production of the drug and its analogue in one production should have caused a conflict of interest between the American AbbVie and the Russian R-Farm. But apparently, R-Farm has agreements with foreigners that they will withdraw their medicines from Russia in exchange for royalties from the sale of analogues. It is clear that Americans will prefer to receive royalties from generic sales rather than start a futile competitive race with a cheaper Russian medicine.

2018: R-Farm lose three big disputes to Nativa

Since April 20, 2018, Nativa has consistently won three major disputes over the collection of debts from R-Pharm, the total amount of which exceeded 400 million rubles. The latest dispute was ruled on May 24, 2018. Read more here.

2016: FAS rejected R-Pharm's claims against BIOCAD and Pharmstandard

At the end of June 2016 Federal Antimonopoly Service (FAS) , R-Farm, the distributor of the Indian company Dr. Reddy's, recognized the claims of rituximab, a drug against blood cancer, as unfounded. The "Third Extra" rule fulfilled its role and protected the investments of Russian companies in the development of the domestic pharmaceutical industry. Recall that two Russian companies submitted applications for the tender, which invested in organizing the production of a complex high-tech drug on the territory - Russia this is BIOCAD "" (Pharmstandard localization of the production of the drug rituximab developed by Roche) and one foreign Dr. Reddy's. Under the "Third Extra" rule, a third company's application was rejected.

"The state protects the interests of enterprises that invest in creating a strong production base of high-tech medicines in Russia. Those enterprises that invest in the development of the domestic pharmaceutical industry should receive priority. The Indian company Dr. Reddy's does not have its own factories in our country, it has not invested in Russian production. Therefore, the rule "Third extra" was used quite reasonably, "- comments on the situation, the general director of BIOCAD Dmitry Morozov.

The R-Pharm company was dissatisfied with the results of the auction and decided to challenge them by contacting the Federal Antimonopoly Service with complaints about the actions of the organizer - the Ministry of Health of the Russian Federation. Representatives of R-Pharm stated that Pharmstandard and BIOCAD products do not have a certificate of origin in the form of ST-1, which was not true. The document is issued by the Russian Chamber of Commerce and Industry and confirms the fact of production or a significant degree of processing of products in Russia. If this certificate is not available, it means that the Russian origin of the drug has not been proven and at the auction it is in the same conditions as imported. All the necessary certificates were provided during the consideration of the complaint to the FAS. As a result, the Federal Antimonopoly Service of Russia recognized the complaints of R-Pharm to the Ministry of Health of the Russian Federation as unfounded, and the results of the auction remained in force.

Localization, ensuring a full cycle of drug production is a guarantee of the quality of the drug. There are necessary opportunities to directly monitor the compliance of manufactured drugs with Russian and international standards. If the drug is produced in another country, then there is no way to track all stages of its production, therefore, it is impossible to be sure of the quality of such a medicine. That is why, according to the law of the Russian Federation, any drug produced and registered in another country in the territory of the Russian Federation is obliged to pass quality control.

According to the legislation of the Russian Federation, in order to register a biosimilar in our country, it is necessary to conduct clinical studies with the participation of Russians. However, there is no information on the import of Dr. Reddy's into our country for clinical trials.

2001: Founding of the Company

The company was founded in 2001.

Notes